XtalPi Expands AI-Driven Lab Automation With BASF Workstation Deployment

QuantumPharm, Inc. ( (HK:2228) ) just unveiled an announcement.

XtalPi has strengthened its position in automated chemistry by successfully deploying an advanced automated formulation stability testing workstation for BASF, a major global chemical producer. The system integrates sample management, analytical testing, and data management, underscoring XtalPi’s ability to provide highly specialized, scalable robotic laboratory solutions to top-tier industrial clients.

The project at BASF showcases the maturity of XtalPi’s modular, customizable platforms, which are already used in drug discovery, chemical synthesis, and advanced materials research, and generate high-quality structured data to power proprietary AI models. By expanding its standardized platform plus agile customization model into large-scale chemicals and renewable energy, and partnering with global leaders such as Sinopec and major research institutions, XtalPi is positioning itself as core infrastructure for AI-driven R&D across multiple trillion-dollar markets.

The most recent analyst rating on (HK:2228) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

More about QuantumPharm, Inc.

XtalPi Holdings Limited is an R&D platform founded in 2015 by three physicists from MIT, combining quantum physics, artificial intelligence, and robotics. The company delivers digital and intelligent R&D solutions to clients in pharmaceuticals, materials science, agricultural technology, energy, new chemicals, and cosmetics, with a focus on standardized automation systems and high-performance cloud computing.

Average Trading Volume: 74,526,710

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$48.52B

See more insights into 2228 stock on TipRanks’ Stock Analysis page.